Myalgic Encephalomyelitis/chronic Fatigue Syndrome Patients Exhibit Altered T Cell Metabolism and Cytokine Associations

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2019 Dec 13

PMID 31830003

Citations 71

Authors

Alexandra H Mandarano

Jessica Maya

Ludovic Giloteaux

Daniel L Peterson

Marco Maynard

C Gunnar Gottschalk

Maureen R Hanson

Affiliations

Soon will be listed here.

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease with no known cause or mechanism. There is an increasing appreciation for the role of immune and metabolic dysfunction in the disease. ME/CFS has historically presented in outbreaks, often has a flu-like onset, and results in inflammatory symptoms. Patients suffer from severe fatigue and postexertional malaise. There is little known about the metabolism of specific immune cells in patients with ME/CFS. To investigate immune metabolism in ME/CFS, we isolated CD4+ and CD8+ T cells from 53 patients with ME/CFS and 45 healthy controls. We analyzed glycolysis and mitochondrial respiration in resting and activated T cells, along with markers related to cellular metabolism and plasma cytokines. We found that ME/CFS CD8+ T cells had reduced mitochondrial membrane potential compared with those from healthy controls. Both CD4+ and CD8+ T cells from patients with ME/CFS had reduced glycolysis at rest, whereas CD8+ T cells also had reduced glycolysis following activation. Patients with ME/CFS had significant correlations between measures of T cell metabolism and plasma cytokine abundance that differed from correlations seen in healthy control subjects. Our data indicate that patients have impaired T cell metabolism consistent with ongoing immune alterations in ME/CFS that may illuminate the mechanism behind this disease.

Citing Articles

mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS.

Bar-Tana J J Transl Med. 2025; 23(1):297.

PMID: 40059164 PMC: 11892318. DOI: 10.1186/s12967-025-06220-z.

The search for a blood-based biomarker for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS): from biochemistry to electrophysiology.

Clarke K, Kingdon C, Hughes M, Lacerda E, Lewis R, Kruchek E J Transl Med. 2025; 23(1):149.

PMID: 39905423 PMC: 11792299. DOI: 10.1186/s12967-025-06146-6.

Tetrahydrobiopterin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Friend or Foe?.

Rahman A, Benko A, Bulbule S, Gottschalk C, Arnold L, Roy A Biomolecules. 2025; 15(1).

PMID: 39858496 PMC: 11763651. DOI: 10.3390/biom15010102.

Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence.

Scheibenbogen C, Wirth K J Cachexia Sarcopenia Muscle. 2024; 16(1):e13669.

PMID: 39727052 PMC: 11671797. DOI: 10.1002/jcsm.13669.

Transcriptional reprogramming primes CD8+ T cells toward exhaustion in Myalgic encephalomyelitis/chronic fatigue syndrome.

Iu D, Maya J, Vu L, Fogarty E, McNairn A, Ahmed F Proc Natl Acad Sci U S A. 2024; 121(50):e2415119121.

PMID: 39621903 PMC: 11648872. DOI: 10.1073/pnas.2415119121.

References

Brenu E, Van Driel M, Staines D, Ashton K, Ramos S, Keane J . Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med. 2011; 9:81. PMC: 3120691. DOI: 10.1186/1479-5876-9-81. View

Cliff J, King E, Lee J, Sepulveda N, Wolf A, Kingdon C . Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Front Immunol. 2019; 10:796. PMC: 6477089. DOI: 10.3389/fimmu.2019.00796. View

Naviaux R, Naviaux J, Li K, Bright A, Alaynick W, Wang L . Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2016; 113(37):E5472-80. PMC: 5027464. DOI: 10.1073/pnas.1607571113. View

Hornig M, Montoya J, Klimas N, Levine S, Felsenstein D, Bateman L . Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015; 1(1). PMC: 4465185. DOI: 10.1126/sciadv.1400121. View

Vacaflores A, Freedman S, Chapman N, Houtman J . Pretreatment of activated human CD8 T cells with IL-12 leads to enhanced TCR-induced signaling and cytokine production. Mol Immunol. 2016; 81:1-15. PMC: 5201458. DOI: 10.1016/j.molimm.2016.11.008. View

Buttgereit F, Burmester G, Brand M . Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today. 2000; 21(4):192-9. DOI: 10.1016/s0167-5699(00)01593-0. View

Akdis M, Aab A, Altunbulakli C, Azkur K, Costa R, Crameri R . Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016; 138(4):984-1010. DOI: 10.1016/j.jaci.2016.06.033. View

Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E . Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 2009; 30(4):470-6. View

Previte D, OConnor E, Novak E, Martins C, Mollen K, Piganelli J . Reactive oxygen species are required for driving efficient and sustained aerobic glycolysis during CD4+ T cell activation. PLoS One. 2017; 12(4):e0175549. PMC: 5398529. DOI: 10.1371/journal.pone.0175549. View

10.

Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L . PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015; 6:6692. PMC: 4389235. DOI: 10.1038/ncomms7692. View

11.

Bantug G, Galluzzi L, Kroemer G, Hess C . The spectrum of T cell metabolism in health and disease. Nat Rev Immunol. 2017; 18(1):19-34. DOI: 10.1038/nri.2017.99. View

12.

Zalocusky K, Kan M, Hu Z, Dunn P, Thomson E, Wiser J . The 10,000 Immunomes Project: Building a Resource for Human Immunology. Cell Rep. 2018; 25(2):513-522.e3. PMC: 6263160. DOI: 10.1016/j.celrep.2018.09.021. View

13.

Yin Y, Choi S, Xu Z, Perry D, Seay H, Croker B . Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med. 2015; 7(274):274ra18. PMC: 5292723. DOI: 10.1126/scitranslmed.aaa0835. View

14.

Tomas C, Brown A, Newton J, Elson J . Mitochondrial complex activity in permeabilised cells of chronic fatigue syndrome patients using two cell types. PeerJ. 2019; 7:e6500. PMC: 6398432. DOI: 10.7717/peerj.6500. View

15.

Jones R, Thompson C . Revving the engine: signal transduction fuels T cell activation. Immunity. 2007; 27(2):173-8. DOI: 10.1016/j.immuni.2007.07.008. View

16.

Myhill S, Booth N, McLaren-Howard J . Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009; 2(1):1-16. PMC: 2680051. View

17.

Smits B, van den Heuvel L, Knoop H, Kusters B, Janssen A, Borm G . Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion. 2011; 11(5):735-8. DOI: 10.1016/j.mito.2011.05.005. View

18.

Bengsch B, Johnson A, Kurachi M, Odorizzi P, Pauken K, Attanasio J . Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity. 2016; 45(2):358-73. PMC: 4988919. DOI: 10.1016/j.immuni.2016.07.008. View

19.

Armstrong C, McGregor N, Butt H, Gooley P . Metabolism in chronic fatigue syndrome. Adv Clin Chem. 2014; 66:121-72. DOI: 10.1016/b978-0-12-801401-1.00005-0. View

20.

Booth N, Myhill S, McLaren-Howard J . Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med. 2012; 5(3):208-20. PMC: 3403556. View